Literature DB >> 4570986

Immune response to Cryptococcus neoformans soluble polysaccharide. I. Serological assay for antigen and antibody.

T R Kozel, J Cazin.   

Abstract

Chromium chloride was used as a coupling agent for the conjugation of purified cryptococcal polysaccharide to sheep erythrocytes. Sensitized erythrocytes were used in a passive hemagglutination (PHA) assay for antibody to cryptococcal polysaccharide and a passive hemagglutination inhibition (PHI) assay for antigen. The PHA assay was more sensitive than complement fixation, agglutination, or precipitation tests for antibody. The PHI assay could detect submicrogram quantities of soluble polysaccharide. Antigen or antibody could be detected in serum or spinal fluid from seven of eight patients with cryptococcosis. Tests for antigen or antibody were negative with sera from patients with histoplasmosis, blastomycosis, coccidioidomycosis, aspergillosis, or allescheriosis. A low frequency (3%) of positive reactors for antibody was found among sera from normal persons and from persons with unrelated diseases; whereas, all tests for antigen were negative. The assay showed a high degree of sensitivity for immunoglobulins of the immunoglobulin M class; however, cryptococcal antibody of the immunoglobulin G class was also detected. The immunological specificity of the polysaccharide preparation was due to carbohydrate rather than to protein associated with the polysaccharide.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4570986      PMCID: PMC422317          DOI: 10.1128/iai.5.1.35-41.1972

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  CRYPTOCOCCUS NEOFORMANS POLYSACCHARIDE: STUDIES OF SEROLOGIC PROPERTIES AND ROLE IN INFECTION.

Authors:  J E BENNETT; H F HASENCLEVER
Journal:  J Immunol       Date:  1965-06       Impact factor: 5.422

2.  Taxonomy of Cryptococcus neoformans and its variety uniguttulatus.

Authors:  N J KREGER-VAN RIJ
Journal:  Antonie Van Leeuwenhoek       Date:  1961       Impact factor: 2.271

3.  The antigenic compostion of Cryptococcus neoformans. IV. The use of paper chromatography for following purification of the capsular polysaccharide.

Authors:  E E EVANS; R J THERIAULT
Journal:  J Bacteriol       Date:  1953-05       Impact factor: 3.490

4.  Chromic chloride: a coupling reagent for passive hemagglutination reactions.

Authors:  E R Gold; H H Fudenberg
Journal:  J Immunol       Date:  1967-11       Impact factor: 5.422

5.  The indirect fluorescent antibody test for the detection of antibody in human cryptococcal disease.

Authors:  R A Vogel
Journal:  J Infect Dis       Date:  1966-12       Impact factor: 5.226

6.  Serum fluorescent antibody and immunoglobulin estimations in candidosis.

Authors:  T Lehner
Journal:  J Med Microbiol       Date:  1970-08       Impact factor: 2.472

7.  Serologic tests in diagnosis and prognosis of cryptococcosis.

Authors:  M A Gordon; D K Vedder
Journal:  JAMA       Date:  1966-09-19       Impact factor: 56.272

8.  Patterns of human antibody reactions in coccidioidomycosis.

Authors:  Y Sawaki; M Huppert; J W Bailey; Y Yagi
Journal:  J Bacteriol       Date:  1966-01       Impact factor: 3.490

9.  Use of erythrocytes sensitized with purified pneumococcal polysaccharides for the assay of antibody and antibody-producing cells.

Authors:  P J Baker; P W Stashak; B Prescott
Journal:  Appl Microbiol       Date:  1969-03

10.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

View more
  16 in total

1.  Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D.

Authors:  R Ikeda; S Nishimura; A Nishikawa; T Shinoda
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

2.  Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.

Authors:  G Nussbaum; S Anandasabapathy; J Mukherjee; M Fan; A Casadevall; M D Scharff
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.

Authors:  T F Eckert; T R Kozel
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

4.  Induction of humoral antibody response by soluble polysaccharide of Cryptococcus neoformans.

Authors:  T R Kozel; J Cazin
Journal:  Mycopathol Mycol Appl       Date:  1974-10-15

5.  Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis.

Authors:  T R Kozel; R P Mastroianni
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

Review 6.  Immunity in cryptococcosis: an overview.

Authors:  R A Fromtling; H J Shadomy
Journal:  Mycopathologia       Date:  1982-03-19       Impact factor: 2.574

7.  Challenge of Drosophila melanogaster with Cryptococcus neoformans and role of the innate immune response.

Authors:  Yiorgos Apidianakis; Laurence G Rahme; Joseph Heitman; Frederick M Ausubel; Stephen B Calderwood; Eleftherios Mylonakis
Journal:  Eukaryot Cell       Date:  2004-04

8.  Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide.

Authors:  F Dromer; J Salamero; A Contrepois; C Carbon; P Yeni
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

9.  Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.

Authors:  Suzanne Brandt; Peter Thorkildson; Thomas R Kozel
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

10.  Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection.

Authors:  J Mukherjee; L A Pirofski; M D Scharff; A Casadevall
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.